Features of anesthetic management and anesthetic risks in patients taking combined oral contraceptives and menopausal hormone therapy

Authors:

Abstract
This review is based on the analysis of domestic and foreign studies published in peer-reviewed medical journals, and clinical guidelines devoted to anesthetic management of patients receiving combined oral contraceptives and menopausal hormone therapy. For the search of publications, the PubMed database and specialized Russian journals were used. The review included studies published in 1990–2025, with emphasis on systematic reviews, randomized controlled trials, large cohort studies, and current clinical guidelines. Combined oral contraceptives and menopausal hormone therapy are widely used in gynecology; however, they increase the risk of venous thromboembolic complications, especially in the perioperative period. Anesthetic management requires careful assessment of thrombotic risk, consideration of interactions of hormonal drugs with anesthetics, sugammadex, and antibiotics, as well as an individualized approach to continuation or discontinuation of therapy. It is recommended to discontinue oral forms of combined oral contraceptives and menopausal hormone therapy 4–6 weeks before high-risk operations, to give preference to transdermal forms of menopausal hormone therapy, to conduct enhanced thromboprophylaxis with low-molecular-weight heparins, and to mandatory inform patients about the need for additional contraception after the use of sugammadex. Particular attention should be given to patients with thrombophilias and comorbidity. Systematization of data contributes to improving the safety of anesthetic management in this category of patients.

This publication has 11 references indexed in Scilit: